Starling Oncology, Inc. (DFPH) Operating income 2020–2025
Starling Oncology, Inc. (DFPH) annual operating income history from SEC filings — each fiscal year as reported.
-$36.1MFY2025 · since FY2020: -$8.2M → -$36.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$36.1M | +40.0% |
| FY2024 | -$60.1M | +21.9% |
| FY2023 | -$77.0M | +6.0% |
| FY2022 | -$82.0M | -78.7% |
| FY2021 | -$45.9M | -459.4% |
| FY2020 | -$8.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DFPH financial trends
DFPH RevenueDFPH Net incomeDFPH Net marginDFPH Gross profitDFPH Gross marginDFPH Operating marginDFPH Operating cash flowDFPH Free cash flowDFPH Capital expendituresDFPH Return on equityDFPH Stock buybacksDFPH Dividends paidDFPH Total assetsDFPH Total liabilitiesDFPH Shareholders’ equityDFPH overview →